Contrasting CAMP4 Therapeutics (NASDAQ:CAMP) & Bicycle Therapeutics (NASDAQ:BCYC)

Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) and CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Valuation & Earnings

This table compares Bicycle Therapeutics and CAMP4 Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bicycle Therapeutics $72.86 million 3.06 -$218.96 million ($2.03) -1.57
CAMP4 Therapeutics $3.50 million 69.20 -$80.40 million ($2.14) -1.80

CAMP4 Therapeutics has lower revenue, but higher earnings than Bicycle Therapeutics. CAMP4 Therapeutics is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bicycle Therapeutics and CAMP4 Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bicycle Therapeutics -169.75% -26.02% -22.30%
CAMP4 Therapeutics -2,276.33% -182.39% -74.87%

Risk and Volatility

Bicycle Therapeutics has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, CAMP4 Therapeutics has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Bicycle Therapeutics and CAMP4 Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bicycle Therapeutics 1 4 5 0 2.40
CAMP4 Therapeutics 1 1 8 1 2.82

Bicycle Therapeutics presently has a consensus target price of $13.57, suggesting a potential upside of 326.77%. CAMP4 Therapeutics has a consensus target price of $10.44, suggesting a potential upside of 170.58%. Given Bicycle Therapeutics’ higher probable upside, analysts plainly believe Bicycle Therapeutics is more favorable than CAMP4 Therapeutics.

Insider and Institutional Ownership

86.2% of Bicycle Therapeutics shares are held by institutional investors. 22.0% of Bicycle Therapeutics shares are held by company insiders. Comparatively, 21.7% of CAMP4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Bicycle Therapeutics beats CAMP4 Therapeutics on 9 of the 14 factors compared between the two stocks.

About Bicycle Therapeutics

(Get Free Report)

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a focus on cancer. Founded in 2009, the company grew out of research at the University of Cambridge in the United Kingdom and has operations in Cambridge, UK, and Cambridge, Massachusetts. The company’s proprietary Bicycle platform creates small, constrained peptides that can bind to specific biological targets. Bicycle Therapeutics is using this technology to develop treatments that may be designed to reach targets that are difficult for conventional drugs to access.

About CAMP4 Therapeutics

(Get Free Report)

CAMP4 Therapeutics is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases in which the body produces too little of an essential protein. The company’s research focuses on increasing the expression of selected genes to address these protein deficiencies. Its Regulatory Action on RNA (RAP) platform is designed to identify regulatory RNAs that influence gene expression. CAMP4 uses antisense oligonucleotides to target these RNAs, with the goal of adjusting the activity of disease-related genes.

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.